A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age

Summary

This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA. The main goals of the study are to learn how well the vaccine helps the body make an immune response against influenza and what medical problems participants may have after vaccination. Researchers will also compare immune responses in adults 18 to 64 years of age from this study, with immune responses in adults 65 years of age and older from another study.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Influenza, Human

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 64 years

Sex

All

Healthy volunteers

Accepted

Sponsor

GlaxoSmithKline

Last updated on ClinicalTrials.gov

October 9, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites